Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company

Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth

Fineline Cube Feb 6, 2025

Amgen (NASDAQ: AMGN) released its Q4 2024 financial results this week, reporting USD 33.42 billion...

Company

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care

Fineline Cube Feb 6, 2025

Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...

Company Drug

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy

Fineline Cube Feb 6, 2025

Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...

Company Drug

Roche’s Susvimo Approved by FDA for Diabetic Macular Edema

Fineline Cube Feb 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US...

Company Drug

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer

Fineline Cube Feb 6, 2025

The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...

Company Deals

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study

Fineline Cube Feb 6, 2025

Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...

Company Drug

Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study

Fineline Cube Feb 6, 2025

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...

Company Drug

Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Feb 6, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia

Fineline Cube Feb 6, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Deals

Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million

Fineline Cube Feb 6, 2025

China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership...

Company Drug

Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials

Fineline Cube Feb 6, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study

Fineline Cube Feb 6, 2025

China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...

Company Deals

ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management

Fineline Cube Feb 6, 2025

China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...

Company

Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Feb 6, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...

Company Drug

Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378

Fineline Cube Feb 6, 2025

China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...

Company Deals

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms

Fineline Cube Feb 5, 2025

China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...

Company Deals

Becton Dickinson Considers Spinning Off Life Sciences Division

Fineline Cube Feb 5, 2025

US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...

Company Deals

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition

Fineline Cube Feb 5, 2025

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...

Company Deals

Nona Biosciences Partners with Invetx for Animal Health Therapies

Fineline Cube Feb 5, 2025

Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...

Company

AbbVie Reports Strong Q4 and Full-Year 2024 Financials

Fineline Cube Feb 5, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...

Posts pagination

1 … 209 210 211 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.